Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1512762 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.47Day +4.26%Mkt cap $227MP/E (FY) 1.0×1Y +51.5%Off 52W high −43.8%Vol (1Y) 79.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,946 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest15.5% of sh out |
| Days to cover24.4d |
| 13F net flow (QoQ)+1.47% |
| Top-10 13F concentration61.4% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)1.0× |
| Sales (TTM)$46.9M |
| Earnings (TTM)$186.3M |
| Net margin398.4% |
| Sales growth 3Y−41.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+3.5% |
| 1Y+51.5% |
| 3Y−69.5% |
| 5Y−88.7% |
| 10Y−94.3% |
| Since incept. (ann.)−16.7% |
Total return through 2026-07-30 · series begins 2014-11-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)79.8% |
| Ann. volatility (3Y)93.2% |
| Sharpe (1Y)0.87 |
| Sharpe (3Y)0.03 |
| Max drawdown (1Y)−45.8% |
| Max drawdown (3Y)−87.7% |
| Beta (3Y vs SPY)1.32 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 10.4M | $18M | 6.92% | −1.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.5M | $9M | 3.64% | new |
| SAMSARA BIOCAPITAL, LLC | 3.4M | $6M | 2.29% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 3.1M | $5M | 2.08% | +13.7% |
| Kohlberg Kravis Roberts & Co. L.P. | 3.0M | $5M | 2.03% | +0.0% |
| STATE STREET CORP | 2.3M | $4M | 1.55% | +4.6% |
| TWO SIGMA INVESTMENTS, LP | 2.3M | $4M | 1.54% | +356.9% |
| Alyeska Investment Group, L.P. | 2.3M | $4M | 1.50% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.28 | — | $12.3M | +62.0% |
| 2025-12-31 | 2026-03-09 | — | — | $12.7M | +64.9% |
| 2025-09-30 | 2025-11-06 | −$0.31 | — | $11.6M | +91.2% |
| 2025-06-30 | 2025-08-07 | $2.57 | — | $10.3M | −0.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Toripalimab 97% · Product And Service Other 3%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
